4/15/18 Two More Years

I have been on the Ruxolitinib trial for two years now. It has been good so far. The trial was designed to address the symptoms of CLL and prove, disprove, or measure its efficacy in individual patients. The requirements of the trial were that each person enrolled must not be treatment naive, meaning that they…